Capecitabine in carcinoma of the pancreas

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 12, 2006, Pages 1633-1639

  Smith, David B ^a   Neoptolemos, John P ^b  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

5 flourouracil; Adjuvant; Advanced cancer; Capecitabine; Chemotherapy; Gemcitabine; Pancreas; Pancreatic

Indexed keywords

ALBUMIN; ALUMINUM MAGNESIUM HYDROXIDE; ANTIBIOTIC AGENT; CAPECITABINE; CYTIDINE DEAMINASE; CYTOCHROME P450 2C9; FLUOROURACIL; GEMCITABINE; INFUSION FLUID; LOPERAMIDE; OXALIPLATIN; PHENYTOIN; PYRIDOXINE; THYMIDINE PHOSPHORYLASE; WARFARIN;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FEVER; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; EYE IRRITATION; FATIGUE; HAND FOOT SYNDROME; HUMAN; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CARCINOMA; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STOMATITIS; STRUCTURE ANALYSIS; SURVIVAL TIME; THROMBOCYTOPENIA; THRUSH; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; PRODRUGS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 33747032049     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.12.1633     Document Type: Article

References (42)

1. JEMAL A, MURRAY T, WARD E et al.: Cancer statistics 2005. CA Cancer J. Clin. (2005) 55:10-30.
2. BRAMHALL SR, ALLUMWH, JONES AG, ALLW00D A, CUMMINS C, NEOPTOLEMOS JP: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br. J. Surg. (1995) 82(1):111-115.
3. PLATH T, PETERS M, DETJEN K et al.: Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. J. Natl. Cancer Inst. (2002) 94:129-142.
4. CARTER SK, COMIS RL: The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat. Rev. (1975) 2:193-214.
5. CROWN J, CASPER ES, BOTET J et al.: Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J. Clin. Oncol. (1991) 9: 1682-1686.
6. DECAPRIO JA, MAYER RJ, GONIN R, ARBUCK SG: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a Phase II trial. J. Clin. Oncol. (1991) 9:2128-2133.
7. VAN RIJSWIJK RE, JEZIORSKI K, WAGENER DJ et al.: Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a Phase II study of the EORTC Gastro-Intestinal Tract Cancer Cooperative Group. Eur. J. Cancer (2004) 40:2077-2081.
8. CASPER ES, GREEN MR, KELSEN DP et al.: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs (1994) 12:29-34.
9. CARMICHAEL J, FINK U, RUSSELL RC et al.: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer (1996) 73:101-105.
10. ROTHENBERG ML, MOORE MJ, CRIPPS MC et al.: A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas. Ann. Oncol. (1996) 7:347-353.
11. BURRIS HA III, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15:2403-2413.
12. THIRION. P, MICHIELS S, PICNON JP et al.: Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. (2004) 22(18):3766-3775.
13. MIWA M, URA M, NISHIDA M et al.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer (1998) 34:1274-1281.
14. ISHIKAWA T, UTOH M, SAWADA N et al.: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol. (1998) 55(7):1091-1097.
15. SCHULLER J, CASSIDY J, DUMONT E et al.: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. (2000) 45:291-297.
16. REIGNER B, BLESCH K, WEIDEKAAM E: Capecitabine; a review of its clinical pharmacokinetics. Clin. Pharmacokinet. (2001) 40:85-104.
17. NAKAYAMA Y, INOUE Y, NAGASHIMA N et al.: Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. Anti-Cancer Res. (2005) 25(6A):3755-3761.
18. PASSANTINO L, AMATI L, CIANCIOTTA A et al.: Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages. Immunopharmacol. Immunotoxicol. (2005) 27(1):95-107.
19. JUDSON I, BEALE P, TRIGO J et al.: A human capecitabine excretion balance and pharmacokinetic study after administration of asingle oral dose of 14C-labelled drug. Invest. New Drugs (1999) 17:49-56.
20. TWELVES C, GLYNNE-JONES R, CASSIDY J et al.: Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin. Cancer Res. (1999) 5:1696-1702.
21. POOLE C, GARDINER J, TWELVES C et al.: Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother. Pharmacol. (2002) 49:225-234.
22. CAMIDGE R, REIGNER B, CASSIDY J et al.: Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J. Clin. Oncol. (2005) 23(21):4719-4125.
23. BRICKELL K, PORTER D, THOMPSON P: Phenytoin toxicity due to fluoropyrimidines (5-FU/capecitabine): three case reports. Br. J. Cancer (2003) 89:615-616.
24. REIGNER B, CLIVES, CASSIDY J et al.: Influence of the antacid maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother. Pharmacol. (1999) 43:309-315.
25. BUDMAN DR, MEROPOL NJ, REIGNER B: Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. Clin. Oncol. (1998) 16:1795-1802.
26. SCHEITHAUER W, MCKENDRICK J, BEGBIE S et al.: X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, Phase III trial. Ann. Oncol. (2003) 14(12):1735-1743.
27. VAN CUTSEM E, HOFF PM, BLUM JL et al.: Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with fluorouracil. Ann. Oncol. (2002) 13(3):484-485.
28. SCHULL B, SCHEITHAUER W, KORNEK GV: Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. Onkologie (2003) 26(6):578-580.
29. CARTWRIGHT TH, COHN A, VARKEY JA et al.: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol. (2002) 20(1):160-164.
30. SAWADA N, FUJIMOTO-OUCHI K, ISHIKAWA T et al.: Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc. Am. Assoc. Cancer Res. (2002). (Abstract 5388.)
31. HESS V, SALZBERG M, BORNER M et al.: Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a Phase I/II trial. J. Clin. Oncol. (2003) 21(1):66-68.
32. HEINEMANN V, HOEHLER T, SEIPELT G et al.: Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (GemCap) versus gemcitabine plus oxaliplatin (GemOx): a randomised Phase II trial in advanced pancreatic cancer. Proc. Am. Assoc. Clin. Oncol. (2005) 23. (Abstract 4030).
33. SCHEITHAUER W, SCHULL B, ULRICH-PUR H et al.: Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized Phase II trial. Ann. Oncol. (2003) 14(1):97-104.
34. HERRMANN R, BODOKY G, RUHSTALLER T et al.: Gemcitabine (G) plus capecitabine versus G alone in locally advanced or metastatic pancreatic cancer. A randomized Phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc. Am. Assoc. Clin. Oncol. (2005). (Abstract 4010.)
35. CUNNINGHAM D, CHAU I, STOCKEN D et al.: Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur. J. Cancer (2005) 3(Suppl.):4.
36. CRANE CH, ELLIS LM, ABBRUZZESE JL et al.: Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J. Clin. Oncol. (2006) 24(7):1145-1151.
37. BEN-JOSEF E, SHIELDS AF, VAISHAMPAYAN U et al.: Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. (2004) 59(2):454-459.
38. ITAKURA J, ISHIWATA T, SHEN B et al.: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer (2000) 85:27-34.
39. BRUNS CJ, SOLORZANO CC, HARBISON MT et al.: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. (2000) 60:2926-2935.
40. MOORE M, GOLDSTEIN D, HAMM J et al.: Erlotinib plus compared to gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCNC-CTG). Proc. Am. Assoc. Clin. Oncol. (2005). (Abstract 1).
41. JAVLE R, IYER R, YU J et al.: Gemcitabine, capecitabine and bevacizumab: a Phase II study for advanced pancreatic cancer (APC) patients with good performance status. Proc. Am. Assoc. Clin. Oncol. Gastrointest. Cancer Symp. (2006). (Abstract 117).
42. NEOPTOLEMOS JP, STOCKEN DD, FRIESS H et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. (2004) 350(12):1200-1210.